The European Medicines Agency (EMA) is to scale back operations further as it copes with higher than expected staff losses, triggered by the watchdog's forced relocation from London to Amsterdam because of Brexit.
The smooth transition of the EU drug agency from London to Amsterdam is threatened by delays in the Netherlands, whose bid to win the agency may have been misleading, a top representative of Italian pharmaceuticals told EURACTIV.com.
The preparations for relocating the European Medicines Agency to the Netherlands next year are underway and on schedule, a senior Dutch government official in the EU told EURACTIV.com on Wednesday (31 January), after recent media reports suggested that Italy wants to appeal to the EU Court.
Dutch officials and the head of the European Medicines Agency (EMA) sought yesterday (29 January) to allay any jitters among the agency's 900 London-based staff who are being asked to move to Amsterdam because of Britain's departure from the EU.
Public health organisations and EU lawmakers say the closed-door meetings before the submission of a new drug between the pharma industry and the European Medicines Agency (EMA), a key player in the continent’s healthcare industry, should be more transparent.
Pharmaceutical companies face a multi-million euro bill in regulatory costs regardless of whether the UK reaches a ‘soft’ or ‘hard’ Brexit deal with the European Union, industry leaders warned on Tuesday (19 December).
Amsterdam and Paris won the right to host the two EU agencies that must leave London on Brexit after a dramatic ministerial meeting in Brussels on Monday (20 November) that left both result decided by drawing lots after votes were tied.
In a visit to Rome yesterday (14 November) Bulgarian Prime Minister Boyko Borissov praised his host Paolo Gentiloni for stopping refugees from Libya, and lashed out at EU’s diplomacy, which is led by another Italian, Federica Mogherini.
EU ministers will vote by secret ballot on the relocation of two EU agencies currently based in London at the General Affairs Council on 20 November. The ballot papers will then be destroyed and no record kept.
Slovakia's prime minister, president and parliament speaker pledged yesterday (23 October) to keep to a pro-European path, a day after its Czech neighbours became the latest central European ex-Communists to elect a populist taking a hard line on the EU.
The European Medicines Agency approved 39 new cancer drugs between 2009 and 2013 despite having no evidence that they worked, unnecessarily exposing patients to toxicity, researchers said Thursday (5 October).
In assessing the relocation of the EU drugs agency EMA, old member states have a "moral and political obligation" to give an advantage to those candidate countries that do not currently host another EU agency, Croatia’s health minister told EURACTIV.com.
Athens’ decision to claim the European Medicine Agency's relocation from London sends a message that medicine is “not just a commodity but a social good”, Greece’s Alternate Minister of Foreign Affairs, Georgios Katrougalos, told EURACTIV.com.
The Southern EU member states are exploring the possibility of forming a united camp regarding the relocation of the European Medicines Agency from London after Brexit, Greece’s Deputy Foreign Minister George Katrougalos said.
The European Medicines Agency (EMA) presented on Tuesday (1 August) a business continuity plan aimed at tackling the potential challenges poised by its relocation from London to another member state after the Brexit decision.
Hosting the European Medicines Agency brings considerable economic benefits to the host city as the service employs more than 1,000 people, paid by the EU. Athens and Milan are keen to secure a slice of this lucrative pie.
The European Medicines Agency (EMA) is not a toy to be played with by politicians, Edith Schippers told EURACTIV.com. The decision on the agency's relocation should be based on the European Commission's assessment, she argues in an interview.